Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Department of Clinical Research, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Brain. 2021 Mar 3;144(2):636-654. doi: 10.1093/brain/awaa408.
As the clinical failure of glioblastoma treatment is attributed by multiple components, including myelin-associated infiltration, assessment of the molecular mechanisms underlying such process and identification of the infiltrating cells have been the primary objectives in glioblastoma research. Here, we adopted radiogenomic analysis to screen for functionally relevant genes that orchestrate the process of glioma cell infiltration through myelin and promote glioblastoma aggressiveness. The receptor of the Nogo ligand (NgR1) was selected as the top candidate through Differentially Expressed Genes (DEG) and Gene Ontology (GO) enrichment analysis. Gain and loss of function studies on NgR1 elucidated its underlying molecular importance in suppressing myelin-associated infiltration in vitro and in vivo. The migratory ability of glioblastoma cells on myelin is reversibly modulated by NgR1 during differentiation and dedifferentiation process through deubiquitinating activity of USP1, which inhibits the degradation of ID1 to downregulate NgR1 expression. Furthermore, pimozide, a well-known antipsychotic drug, upregulates NgR1 by post-translational targeting of USP1, which sensitizes glioma stem cells to myelin inhibition and suppresses myelin-associated infiltration in vivo. In primary human glioblastoma, downregulation of NgR1 expression is associated with highly infiltrative characteristics and poor survival. Together, our findings reveal that loss of NgR1 drives myelin-associated infiltration of glioblastoma and suggest that novel therapeutic strategies aimed at reactivating expression of NgR1 will improve the clinical outcome of glioblastoma patients.
由于胶质母细胞瘤治疗的临床失败归因于多个因素,包括髓鞘相关浸润,评估这种过程的分子机制并鉴定浸润细胞一直是胶质母细胞瘤研究的主要目标。在这里,我们采用放射基因组学分析来筛选功能相关基因,这些基因通过髓鞘协调胶质瘤细胞浸润过程并促进胶质母细胞瘤侵袭性。Nogo 配体的受体(NgR1)通过差异表达基因(DEG)和基因本体论(GO)富集分析被选为顶级候选物。NgR1 的功能获得和功能丧失研究阐明了其在体外和体内抑制髓鞘相关浸润的潜在分子重要性。在分化和去分化过程中,NgR1 通过 USP1 的去泛素化活性可逆调节神经胶质细胞瘤细胞在髓鞘上的迁移能力,抑制 ID1 的降解以下调 NgR1 表达。此外,匹莫齐特是一种著名的抗精神病药物,通过靶向 USP1 的翻译后修饰而上调 NgR1,使神经胶质瘤干细胞对髓鞘抑制敏感,并抑制体内髓鞘相关浸润。在原发性人脑胶质母细胞瘤中,NgR1 表达下调与高度浸润性特征和不良预后相关。总之,我们的研究结果表明,NgR1 的缺失驱动胶质母细胞瘤的髓鞘相关浸润,并表明旨在重新激活 NgR1 表达的新的治疗策略将改善胶质母细胞瘤患者的临床结局。